Iovance Biotherapeutics Inc Corporate Call Transcript
Welcome to the Iovance Biotherapeutics Special Update Conference Call. My name is Michelle, and I will be your operator for today's call.
At this time, all participants are in listen only mode. Later, we will conduct a question-and-answer session. (Operator Instructions) Please note that this conference is being recorded.
I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, please begin.
Thank you, operator. Good morning, and thank you for joining our conference call to discuss recent corporate, clinical and regulatory updates. These updates were highlighted in a press release we issued earlier this morning, which can also be found on our corporate website at iovance.com.
On today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction and summary about our acquisition of Proleukin, a recombinant human interleukin-2
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |